Benzofuran-indozazaone derivatives, their synthesis methods and applications

By using the [4+3] cycloaddition reaction of indene-2-carboxaldehyde compounds and orange ketone imine compounds under NHC catalyst, the cumbersome and costly synthesis of benzofuran-indene-azahexanone skeletons in the prior art has been solved, and a highly efficient and convenient synthesis of polycyclic fused azahexanone compounds has been achieved.

CN123106691APending Publication Date: 2026-11-17ZHEJIANG NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611489109.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing methods for synthesizing benzofuran-indozazepine skeletons suffer from cumbersome reaction steps, poor substrate universality, high synthesis costs, and difficulty in achieving large-scale production.

Method used

Benzofuranoindoazine derivatives were synthesized by a [4+3] cycloaddition reaction of indene-2-carboxaldehyde compounds and orange ketone imine compounds under NHC catalyst. The reaction conditions were mild and the operation was simple.

Benefits of technology

This method enables the green and efficient synthesis of various benzofuranoindozazaone compounds with diverse structures. The raw materials are readily available, the target product yield is high, and the substrates have a wide range of applicability, making it suitable for the preparation of drug molecules such as protease inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
Patent Text Reader

Abstract

This invention discloses a benzofuran-indozazaone derivative, its synthesis method, and its applications. Using indole-2-carboxaldehyde compounds as raw materials, this invention facilitates the [4+3] cycloaddition reaction with orange ketone imine compounds under NHC catalysis, thereby simply and efficiently synthesizing a series of benzofuran-indozazaone derivatives with different structures. The benzofuran-indozazaone derivatives of this invention can be further converted into drug molecules such as protease inhibitors. The method of this invention utilizes readily available raw materials, is simple to operate, and operates under mild reaction conditions, exhibiting a diversity of functional groups.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical intermediate synthesis technology, specifically to a class of benzofuran-indozazepine derivatives, their synthesis methods, and applications. Background Technology

[0002] Benzofuranoindozazepines belong to the typical fused seven-membered nitrogen-containing heterocyclic (ε-lactam) skeleton, possessing both nitrogen atoms and carbonyl functional groups within the ring. This unique fused seven-membered ring structure endows the molecule with excellent flexible conformation, making it a highly sought-after pharmacophore in drug molecule design and development. This type of skeleton is widely found in various marketed drugs and bioactive molecules (A Review on Synthesis, Reactions and Biological Properties of Seven-Membered Heterocyclic Compounds: Azepine, Azepane, Azepinone). Curr. Org. Chem. 2021, 25 (449-506), for example, benzo[a]thiazide drugs such as diltiazem and clenbuterol have been used to treat central nervous system-related diseases, and angiotensin-converting enzyme inhibitors such as cilazapril and benazepril have been widely used in the clinical treatment of hypertension and congestive heart failure. Meanwhile, polycyclic fused azathioprine derivatives have shown significant application potential in several innovative drug development fields (Indole-fused azepines and analogues as anticancer lead molecules: Privileged findings and future directions). Eur. J. Med. Chem. 2017, 142 , 244-265): As a multi-enzyme inhibitor, it exhibits a variety of biological activities depending on the substituents on the parent nucleus molecule, such as inhibiting tumor cell growth, protecting insulin-producing pancreatic β cells, and inhibiting the hyperphosphorylation of tau protein in brain cells of Alzheimer's disease patients (Epoxide-containing side chains enhance antiproliferative activity of paullones). Eur. J. Med. Chem. 2005, 40, 655-661; 9-Cyano-1-azapaullone (Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) Inhibitor Activating Pancreatic β Cell Protection and Replication. J. Med. Chem. 2008, 51 , 2196-2207; Paullones are potent inhibitors of glycogensynthase kinase-3β and cyclin-dependent kinase 5 / p25. FEBS J. 2000, 267 (5983-5994). Therefore, developing efficient and convenient synthetic methods for benzofuran-indozazaone compounds, especially techniques for stereoselectively constructing such skeletons, has significant theoretical research and industrial application value.

[0003] Currently, the reported synthetic strategies for constructing the skeletons of benzofuran-indazapyrones can be mainly divided into three categories: ring expansion strategies, ring-closing metathesis (RCM) strategies, and cycloaddition strategies. (Synthesis of Medium-Sized Heterocycles by Transition-Metal-Catalyzed Intramolecular Cyclization. Molecules 2020, 25 , 3147;Construction of Medium-Sized Rings by GoldCatalysis. Chem. Rev 2021, 121 , 8926-8947; A happy medium: the synthesis of medicinally important medium-sized rings via ring expansion. Chem. Sci. 2020, 11(2876-2881). Among these, the ring expansion strategy is a classic method for constructing seven-membered lactam rings, with the Beckmann rearrangement and Schmidt reaction as typical examples. The ring-closure metathesis (RCM) strategy typically requires the preparation of a diene amide intermediate containing a diene structure, followed by an olefin ring-closure metathesis reaction mediated by a Grubbs catalyst to construct the seven-membered lactam ring. However, both of these synthetic methods generally have significant drawbacks, namely cumbersome reaction steps, poor substrate universality, high synthesis costs, and difficulty in large-scale production, limiting their practical application. In addition, the cycloaddition strategy is also an important route for constructing azirmono-2-one skeletons. Currently, this strategy mainly relies on transition metal catalysis systems, which similarly limits the application range of this type of skeleton.

[0004] In summary, existing methods for synthesizing benzofuran-indozazaone skeletons still have many shortcomings. Developing a new method for constructing benzofuran-indozazaone skeletons that is green, efficient, and has a wide range of substrate applicability remains a key technical problem that urgently needs to be solved in this field. A breakthrough in this method would be of great practical significance for promoting the drug development and application of this type of advantageous pharmacophore. Summary of the Invention

[0005] To address the aforementioned technical problems and shortcomings in the field, this invention provides a class of benzofuran-indozazaone derivatives, their synthesis methods, and applications.

[0006] This invention utilizes indene-2-carboxaldehyde compounds as raw materials, and under the catalysis of an NHC catalyst (triazole azacarbene catalyst), undergoes a [4+3] cycloaddition reaction with orange ketone imine compounds to simply and efficiently synthesize a series of benzofuranoindozazaone derivatives with different structures. The benzofuranoindozazaone derivatives of this invention can be further converted into drug molecules such as protease inhibitors. The method of this invention uses readily available raw materials, is simple to operate, has mild reaction conditions, and exhibits a diversity of functional groups.

[0007] The specific technical solution is as follows: In a first aspect, the present invention provides a class of benzofuran-indozazaone derivatives having molecular structures as shown in Formula 1 or Formula 4: ; ; R 1 It is a hydrogen atom or a mono- or di-substituted chlorine atom (i.e., there is one or two chlorine atoms on the benzene ring). R 2It is a hydrogen atom, a halogen atom (e.g., chlorine, bromine, etc.), an alkoxy group, or a substituted or unsubstituted phenyl group, wherein the substituent on the phenyl group is selected from a halogen atom, an alkyl group, or an alkoxy group; R 3 It is methanesulfonyl (Ms) or p-toluenesulfonyl (Ts); R 4 It is a heteroaryl or a substituted or unsubstituted aryl group (e.g., phenyl), wherein the heteroatom in the heteroaryl group is S, and the substituents on the aryl group (e.g., phenyl) are selected from halogen atoms (e.g., fluorine, chlorine, bromine, etc.), alkyl or alkoxy groups.

[0008] Furthermore, the alkyl group is methyl.

[0009] Furthermore, the alkoxy group is a methoxy group.

[0010] Furthermore, the aryl group is phenyl or naphthyl.

[0011] Furthermore, the heteroaryl group is a thienyl group.

[0012] Secondly, the present invention provides a method for synthesizing the benzofuran-indanezazone derivatives described in the first aspect. The synthesis method includes: Under an inert atmosphere, in the presence of a base and an oxidizing agent [O], compound 3 (e.g., indene-2-carboxaldehyde compounds, which can serve as high-ene dipole starting materials) and compound 2 (e.g., orange ketone imine compounds, which can serve as dipoleophiles) undergo a [4+3] cycloaddition reaction catalyzed by an NHC catalyst to generate benzofuranoindenzazetone derivatives with molecular structures as shown in Formula 1; or, Under an inert atmosphere and in the presence of a base, compounds 3 and 2 undergo a [4+3] cycloaddition reaction catalyzed by an NHC catalyst to generate benzofuran-indozazaone derivatives with the molecular structure shown in Formula 4.

[0013] R in compound 3 1 The definition is the same as the first aspect.

[0014] R in compound 2 2 R 3 R 4 The definition is the same as the first aspect.

[0015] The reaction is a higher-order cycloaddition reaction catalyzed by an NHC catalyst, which can realize the construction of polycyclic fused seven-membered nitrogen heterocycles and achieve green and efficient synthesis of benzofuran-indene-azahexaone derivatives. After the reaction is completed, the product can be separated and characterized by conventional separation and purification methods.

[0016] In some preferred embodiments, the molar ratio of compound 3 to compound 2 is not less than 1.2:1.

[0017] In some preferred embodiments, the reaction is carried out in the presence of a solvent. More preferably, the solvent includes one or more of toluene, dichloromethane, n-hexane, tetrahydrofuran, and trifluorotoluene. Even more preferably, the solvent includes at least one of n-hexane and trifluorotoluene, which corresponds to the best reaction effect.

[0018] In some preferred embodiments, the reaction is carried out in the presence of a 4 Å molecular sieve. The 4 Å molecular sieve serves to absorb water and act as a drying agent.

[0019] In some preferred embodiments, the reaction temperature is 0-35°C.

[0020] In some preferred embodiments, the reaction time is 3-48 hours, such as 4 hours, 16 hours, etc.

[0021] In some preferred embodiments, the inert atmosphere is a nitrogen atmosphere and / or an argon atmosphere.

[0022] In some preferred embodiments, the NHC catalyst comprises catalyst C: ; Wherein, -C6F5 represents pentafluorophenyl.

[0023] In some preferred embodiments, the molar ratio of the NHC catalyst to compound 2 is not less than 0.2:1.

[0024] In some preferred embodiments, the base includes one or more of potassium acetate, sodium acetate, sodium benzoate, and potassium benzoate. More preferably, the base includes at least one of potassium benzoate and potassium acetate.

[0025] In some preferred embodiments, the molar ratio of the base to compound 2 is not less than 1:1.

[0026] In some preferred embodiments, the oxidant [O] includes 3,3',5,5'-tetratert-butyl-4,4'-biphenylquinone (DQ for short).

[0027] In some preferred embodiments, the molar ratio of the oxidant [O] to compound 2 is not less than 1.2:1.

[0028] Thirdly, the present invention provides the use of the synthetic method described in the second aspect in the preparation of medicaments for treating and / or preventing diseases related to abnormal protease activity.

[0029] Compared with existing methods for synthesizing polycyclic fused azathiones, the raw materials of this invention are readily available, the operation is simple, and the reaction can be carried out in a green and efficient manner to construct benzofuran-indozathiones.

[0030] Compared with the prior art, the beneficial effects of this invention are as follows: 1) Synthetic subcompound 3 is easy to prepare in large quantities and can be used to synthesize benzofuran-indozazepine ketones of different types and structures.

[0031] 2) Compound 2 participates in the reaction under mild conditions, is simple to operate, has a high yield of the target product, has a wide range of applicable substrates, high atom economy, and can efficiently synthesize benzofuran-indozazaone compounds with different substituents.

[0032] 3) This invention can synthesize protease inhibitors quickly, efficiently, and conveniently. Detailed Implementation

[0033] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Operating methods not specifically specified in the following embodiments are generally performed under conventional conditions or as recommended by the manufacturer.

[0034] The chemical reagents used in the following examples are all commercially available or obtained by existing technology. For example, compound 3 can be obtained according to Organocatalytic regiospecific synthesis of 1H-indene-2-carbaldehyde derivatives: suppression of cycloolefin isomerisation by employing sterically demanding catalysts. Org. Biomol. Chem., 2017 ,15, Compound 2 can be synthesized using the methods reported in literature 1355-1362, and can be synthesized using the Palladium-catalyzed [6+4] cycloaddition with π-allyl all-carbon 1,6-dipole for the synthesis of ten-membered heterocycles. Org. Chem. Front. , 2024, 11 The synthesis method reported in literature such as 1299-1304.

[0035] Example 1: The specific procedure included: accurately weighing compound 3a (0.12 mmol), compound 2a (0.1 mmol), NHC catalyst C (0.02 mmol), oxidant DQ (0.12 mmol), potassium benzoate (0.1 mmol), and 50 mg of 4 Å molecular sieve using an analytical balance, and adding 2 mL of ultra-dry n-hexane to a dry reaction tube under a nitrogen atmosphere. Ms represents the methanesulfonyl group. The reaction was carried out at 35 °C for 48 h. After the reaction was complete, the product was directly subjected to silica gel column chromatography (eluting buffer: petroleum ether / dichloromethane = 4 / 1, v / v) to obtain an orange solid product, namely benzofuranoindozaza derivative 1a (40.6 mg, yield 92%, ee value 99%). The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0036] Example 2: Two different types of raw materials were used, where Ts represents p-toluenesulfonyl group. The reaction steps and operations were the same as in Example 1. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 1b (45.4 mg, yield 88%, ee value 99%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0037] Example 3: Two different types of raw materials were used, with Ms representing methanesulfonyl group. The reaction steps and operations were the same as in Example 1. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 1c (40.1 mg, yield 87%, ee value 99%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0038] Example 4: Two different types of raw materials were used, with Ms representing methanesulfonyl group. The reaction steps and operations were the same as in Example 1. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 1d (43.3 mg, yield 92%, ee value 99%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0039] Example 5: The raw materials were changed to three different types, and the reaction steps and operations were the same as in Example 1. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 1e (43.6 mg, yield 88%, ee value 99%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0040] Example 6: The specific procedure included: accurately weighing compound 3a (0.12 mmol), compound 2a (0.1 mmol), NHC catalyst C (0.02 mmol), and potassium acetate (0.1 mmol) using an analytical balance, and adding 2 mL of ultra-dry trifluorotoluene to a dry reaction tube under a nitrogen atmosphere. Ms represents the methanesulfonyl group. The reaction was carried out at 0 °C for 3 h. After the reaction was complete, the product was directly analyzed by silica gel column chromatography (elution buffer: petroleum ether / dichloromethane = 4 / 1, v / v) to obtain an orange solid product, namely the benzofuranoindozaza derivative 4a (40.6 mg, yield 92%, ee value 98%). The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0041] Example 7: Two different types of raw materials were used, with Ts representing p-toluenesulfonyl group. The reaction steps and operations were the same as in Example 6. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 4b (34.5 mg, yield 78%, ee value 99%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0042] Example 8: Two different types of raw materials were used, with Ms representing methanesulfonyl group. The reaction steps and operations were the same as in Example 6. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 4c (42.4 mg, yield 92%, ee value 97%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0043] Example 9: Two different types of raw materials were used, with Ms representing methanesulfonyl group. The reaction steps and operations were the same as in Example 6. The reaction was stopped, and after post-processing, the target product, namely benzofuranoindozaza derivative 4d (36.9 mg, yield 78%, ee value 97%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0044] Example 10: Three different types of raw materials were used, with Ms representing methanesulfonyl group. The reaction steps and operations were the same as in Example 6. The reaction was stopped, and after post-processing, the target product, namely the benzofuranoindozaza derivative 4e (33.5 mg, yield 70%, ee value 97%), was obtained as an orange solid. The target product was confirmed by nuclear magnetic resonance spectroscopy, high-resolution mass spectrometry, and high-performance liquid chromatography.

[0045] Example 11: The benzofuranoindozaza derivatives of this invention can be used to rapidly, efficiently, and conveniently synthesize glycine transporter 1 inhibitor model molecules, namely compound 7 (Atropisomeric 4-Phenyl-4H-1,2,4-triazoles as Selective Glycine Transporter 1 Inhibitors). J. Med. Chem. , 2013, 56 (Reported in documents such as 5744-5756). A one-pot, two-step method was employed, specifically as follows: Compound 1b (1 mmol), cuprous chloride (4 mmol), and sodium borohydride (4 mmol) were accurately weighed using an analytical balance. 10 mL of ultra-dry ethanol was measured using a syringe and added sequentially to a dry reaction tube under a nitrogen atmosphere. The reaction was carried out at 50 °C for 2 h. After the reaction was complete, 3.0 mL of water was added to quench the reaction. The ethanol solvent was removed by vacuum distillation to obtain an aqueous phase, which was extracted three times with 5 mL of dichloromethane each time. The organic phases were combined, dried over anhydrous sodium sulfate, and the crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1, v / v). This yielded an orange solid product 5 (345 mg, yield 95%, ee value 99%). Compound 5 (0.48 mmol) was accurately weighed using an analytical balance and added to 5 mL of toluene under a nitrogen atmosphere. Lawesson's reagent was added, and the mixture was reacted at 60 °C for 2 h. After the reaction, the crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1, v / v) to give a yellow solid product 6 (154 mg, yield 82%, ee value 99%). Compound 6 (0.3 mmol) was accurately weighed using an analytical balance and added sequentially to a dry reaction tube under a nitrogen atmosphere with 3.0 mL of acetonitrile, 0.6 mmol of iodomethane, and 0.6 mmol of potassium carbonate. The reaction was carried out at room temperature. After the reaction, the crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 30 / 1, v / v) to give the methylated product. Under a nitrogen atmosphere, the methylated product, tetrahydrofuran (3.0 ml), acetylhydrazine (0.06 mmol), and trifluoroacetic acid (0.15 mmol) were added sequentially to a dry reaction tube, and the reaction was carried out at 80 °C for 48 h. After the reaction was completed, the crude product was purified by silica gel column chromatography (the eluent was changed from petroleum ether / ethyl acetate = 2 / 1 to dichloromethane / ethyl acetate = 1 / 1, v / v) to give the furan-indene-aza derivative white solid product 7 (78 mg, yield 65%, ee value 98%).

[0046] Typical compound characterization data: Benzofuranoindoazolidinone derivative 1a, orange solid. 1 1H NMR (hydrogen NMR) (400 MHz, Chloroform- d ) δ 7.74 – 7.67 (m, 2H), 7.62 – 7.55 (m, 1H), 7.49 – 7.42 (m,3H), 7.35 – 7.23 (m, 6H), 5.73 (s, 1H), 4.16 (d, J = 24.0 Hz, 1H), 3.69 (d, J= 24.0 Hz, 1H), 3.04 (s, 3H);13 C10 NMR (100 MHz, CDCl3) δ 164.32, 155.46, 154.01, 153.19, 144.35, 142.47, 138.28, 134.00, 129.28, 129.18(2C), 128.04, 127.59, 127.23(2C), 126.14, 124.93, 124.85, 123.80, 121.44, 120.91, 115.26, 111.77, 42.09, 40.81, 39.49; ... 26 H 19 The theoretical value of NO4SNa using HRMS (high-resolution mass spectrometry) for [M+Na] + : 464.0932; Measured value: 464.0931.

[0047] Benzofuranoindoazolidinone derivative 1b, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 8.09 – 7.94 (m, 1H), 7.60 – 7.55 (m, 1H), 7.54 – 7.47 (m, 2H), 7.15 (d,J = 7.6 Hz, 2H), 7.01 (d, J = 8.1 Hz, 2H), 5.75 (s, 1H), 3.99 (d, J = 24.1Hz, 1H), 3.61 (d, J = 24.0 Hz, 1H), 2.34 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ162.38, 153.59, 153.29, 152.84, 144.70, 144.19, 142.94, 138.80, 135.06,134.49, 129.50(2C), 129.34(2C), 129.22(2C), 129.07, 127.72, 127.48, 127.29(2C), 126.42, 124.96, 124.66, 123.78, 121.88, 121.35, 115.60, 111.60, 41.00,39.69, 21.81; C 32 H 23 The theoretical HRMS value of NO4SNa [M+Na] + : 540.1245; Measured value: 540.1245.

[0048] Benzofuranoindoazolidinone derivative 1c, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 7.72 – 7.65 (m, 2H), 7.62 – 7.56 (m, 1H), 7.50 – 7.43 (m, 3H), 7.36 –7.24 (m, 5H), 7.03 – 6.95 (m, 2H), 5.69 (s, 1H), 4.15 (d, J = 24.0 Hz, 1H), 3.69 (d, J = 24.0 Hz, 1H), 3.24 (s, 3H); 19 F NMR (376 MHz, Chloroform- d (Fluorine NMR) δ -113.79 (s, 1F); 13 C NMR (100 MHz, Chloroform- d ) δ 164.31, 162.38 (d, J = 247.7 Hz), 155.15, 153.40, 153.22, 144.42, 142.32, 134.08, 133.70 (d, J =3.3 Hz), 129.43, 128.94 (d, J = 8.1 Hz) (2C), 127.67, 125.97, 125.08, 124.92,123.86, 121.43, 120.84, 116.15 (d, J = 21.6 Hz) (2C), 115.35, 111.85, 42.91,40.36, 39.58; C 26 H 18 The theoretical HRMS value of FNO4SNa ([M+Na)) + ): 482.0838; Measured value: 482.0838.

[0049] Benzofuranoindoazolidinone derivative 1d, orange solid. 1 H NMR (400 MHz, Chloroform- d) δ 7.70 – 7.64 (m, 1H), 7.61 – 7.55 (m, 1H), 7.49 – 7.42 (m, 2H), 7.33 –7.20 (m, 7H), 6.88 – 6.80 (m, 1H), 5.82 (s, 1H), 4.15 (d, J = 24.1 Hz, 1H), 4.02 (s, 3H), 3.68 (d, J = 24.0 Hz, 1H), 3.00 (s, 3H); 13 C NMR (100 MHz, Chloroform- d ) δ 164.29, 155.60, 154.36, 145.33, 144.33, 142.57, 142.37,138.30, 133.96, 129.29, 129.15(2C), 128.01, 127.71, 127.58, 127.25(2C),124.82, 124.56, 121.53, 115.64, 113.12, 106.66, 56.26, 41.98, 40.64, 39.47;C 27 H 21 The theoretical HRMS value of NO5SNa ([M+Na)) + ): 494.1038; Measured value: 494.1035.

[0050] Benzofuran-indozazaone derivative 1e, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 7.71 – 7.68 (m, 1H), 7.63 – 7.60 (m, 1H), 7.49 – 7.46 (m, 1H), 7.45 –7.42 (m, 2H), 7.34 – 7.30 (m, 3H), 7.29 (d, J = 0.8 Hz, 1H), 7.28 – 7.26 (m,3H), 5.68 (s, 1H), 4.18 (d, J = 24.4 Hz, 1H), 3.71 (d, J = 24.4 Hz, 1H), 3.05(s, 3H); 13 C NMR (100 MHz, Chloroform- d) δ 163.97, 154.75, 153.77, 153.21,143.98, 142.04, 137.99, 134.80, 131.05, 129.33, 129.30(2C), 129.28, 128.19,127.18(2C), 126.05, 125.07, 123.90, 120.93, 119.95, 115.23, 111.80, 42.12,41.05, 39.21; C 26 H 18 The theoretical HRMS value of ClNO4SNa ([M+Na)) + ): 498.0543; Measured value: 498.0541.

[0051] Benzofuranoindoazolidinone derivative 4a, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 7.56 (d, J = 8.1 Hz, 2H), 7.53 – 7.49 (m, 1H), 7.48 – 7.43 (m, 2H), 7.39– 7.32 (m, 2H), 7.29 – 7.25 (m, 2H), 7.24 – 7.17 (m, 2H), 7.08 – 7.02 (m,1H), 6.69 (d, J = 7.7 Hz, 1H), 4.46 (d, J = 11.0 Hz, 1H), 4.31 – 4.25 (m,1H), 3.80 (s, 3H), 3.76 – 3.64 (m, 2H), 3.06 (q, J = 6.6 Hz, 1H); 13 C NMR (100MHz, Chloroform- d ) δ 175.45, 154.25, 153.14, 142.15, 141.35, 139.58, 129.45(2C), 128.85(2C), 128.06, 127.94, 127.01, 125.60, 125.04, 124.72, 123.96,123.28, 120.10, 113.53, 111.66, 52.38, 51.89, 50.28, 44.31, 31.37; C 26 H 21 The theoretical HRMS value of NO4SNa ([M+Na)) +): 466.1083; Measured value: 466.1083.

[0052] Benzofuranoindoazolidinone derivative 4b, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 8.09 – 7.94 (m, 1H), 7.60 – 7.55 (m, 1H), 7.54 – 7.47 (m, 2H), 7.43 –7.23 (m, 9H), 7.15 (d, J = 7.6 Hz, 2H), 7.01 (d, J = 8.1 Hz, 2H), 5.75 (s,1H), 3.99 (d, J = 24.1 Hz, 1H), 3.61 (d, J = 24.0 Hz, 1H), 2.34 (s, 3H); 13 CNMR (100 MHz, Chloroform- d ) δ 162.38, 153.59, 153.29, 152.84, 144.70, 144.19,142.94, 138.80, 135.06, 134.49, 129.50(2C), 129.34(2C), 129.22(2C), 129.07,127.72, 127.48, 127.29(2C), 126.42, 124.96, 124.66, 123.78, 121.88, 121.35,115.60, 111.60, 41.00, 39.69, 21.81; C 32 H 25 The theoretical HRMS value of NO4SNa ([M+Na)) + ):542.1402; Measured value: 542.1395.

[0053] Benzofuranoindoazolidinone derivative 4c, orange solid. 1 H NMR (400 MHz, Chloroform- d) δ 7.55 – 7.47 (m, 3H), 7.36 – 7.32 (m, 1H), 7.30 – 7.19 (m, 4H), 7.18 –7.11 (m, 2H), 7.08 – 7.03 (m, 1H), 6.66 (d, J = 7.7 Hz, 1H), 4.45 (d, J =11.2 Hz, 1H), 4.23 (m, 1H), 3.81 (s, 3H), 3.75 – 3.60 (m, 2H), 3.13 – 3.01(m, 1H); 19 F NMR (376 MHz, Chloroform- d ) δ -110.75 – -116.07 (m, 1F); 13 C NMR (100 MHz, Chloroform- d ) δ 175.53, 162.55 (d, JC-F = 247.1 Hz), 154.11,153.29, 142.06, 141.51, 135.52 (d, JC-F = 3.4 Hz), 130.55 (d, JC-F = 8.1 Hz)(2C), 128.17, 127.17, 125.65, 125.30, 124.94, 123.93, 123.48, 120.19, 116.54(d, JC-F = 21.5 Hz) (2C), 113.64, 111.79, 51.93, 51.76, 50.37, 44.66, 31.47;C 26 H 20 The theoretical HRMS value of FNO4SNa ([M+Na)) + ): 484.0995; Measured value: 484.0981.

[0054] Benzofuran-indozazone derivative 4d, orange solid. 1 H NMR (400 MHz, Chloroform- d) δ 7.57 – 7.54 (m, 2H), 7.45 – 7.40 (m, 2H), 7.35 – 7.31 (m, 1H), 7.22 –7.15 (m, 3H), 7.09 – 7.06 (m, 1H), 7.06 – 7.02 (m, 1H), 6.76 (d, J = 7.9 Hz,1H), 6.71 (d, J = 7.7 Hz, 1H), 4.49 (d, J = 10.9 Hz, 1H), 4.28 – 4.22 (m,1H), 3.90 (s, 3H), 3.77 (s, 3H), 3.70 – 3.61 (m, 2H), 3.07 – 3.00 (m, 1H); 13 CNMR (100 MHz, Chloroform- d ) δ 175.51, 154.63, 145.32, 142.69, 142.32, 141.37,139.78, 129.49(2C), 128.96(2C), 128.05, 127.98, 127.38, 127.10, 124.78,124.14, 123.96, 113.99, 112.28, 107.21, 56.13, 52.33, 52.18, 50.41, 44.36,31.43; C 27 H 23 The theoretical HRMS value of NO5SNa ([M+Na)) + ): 496.1195; Measured value: 496.1188.

[0055] Benzofuran-indozazaone derivative 4e, orange solid. 1 H NMR (400 MHz, Chloroform- d ) δ 7.58 – 7.54 (m, 2H), 7.53 – 7.49 (m, 1H), 7.43 – 7.38 (m, 1H), 7.38 –7.32 (m, 2H), 7.29 – 7.20 (m, 3H), 7.19 – 7.10 (m, 3H), 5.17 (d, J = 6.6 Hz,1H), 4.66 – 4.53 (m, 1H), 3.76 – 3.65 (m, 1H), 3.61 – 3.48 (m, 4H), 3.02 –2.93 (m, 1H); 13C NMR (100 MHz, Chloroform- d ) δ 173.71, 156.20, 153.03,144.02, 141.45, 139.29, 130.29, 129.38, 129.13, 128.97(2C), 128.27(2C),127.40, 125.51, 125.02, 123.58, 123.40, 120.46, 113.23, 111.79, 55.59, 51.42,46.95, 43.26, 32.10; C 26 H 20 The theoretical HRMS value of ClNO4SNa ([M+Na)) + ): 500.0694; Measured value: 500.0692.

[0056] Compound 7, white solid. 1 H NMR (400 MHz, Chloroform- d ) δ 7.60 – 7.57 (m,3H), 7.53 – 7.50 (m, 1H), 7.41 – 7.32 (m, 4H), 7.21 – 7.10 (m, 5H), 5.85 (s,1H), 4.51 (d, J = 23.3 Hz, 1H), 3.89 (d, J = 23.3 Hz, 1H), 2.73 (s, 3H); 13 CNMR (101 MHz, Chloroform- d ) δ 153.29, 150.83, 150.56, 150.01, 143.36, 143.34,143.18, 137.57, 129.17, 128.83, 127.72, 127.13, 126.96, 126.81, 125.32,124.50, 123.74, 122.78, 119.50, 119.47, 113.47, 112.36, 41.74, 39.26, 12.93.C 27 H 20 Theoretical HRMS value of N3O ([M+H)) + ): 402.1601; Measured value: 402.1606.

[0057] Furthermore, it should be understood that after reading the above description of the present invention, those skilled in the art can make various alterations or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A benzofuranoindozazepine ketone derivative, characterized in that, It has a molecular structure as shown in Formula 1 or Formula 4: ; ; R 1 It is a hydrogen atom or a mono- or di-substituted chlorine atom; R 2 It is a hydrogen atom, a halogen atom, an alkoxy group, or a substituted or unsubstituted phenyl group, wherein the substituent on the phenyl group is selected from a halogen atom, an alkyl group, or an alkoxy group; R 3 It is methanesulfonyl or p-toluenesulfonyl; R 4 It is a heteroaryl or a substituted or unsubstituted aryl group, wherein the heteroatom in the heteroaryl group is S, and the substituents on the aryl group are selected from halogen atoms, alkyl or alkoxy groups.

2. The benzofuranoindozazaone derivative according to claim 1, characterized in that, The alkyl group is methyl; The alkoxy group is a methoxy group; The aryl group is phenyl or naphthyl; The heteroaryl group is a thiophene group.

3. A method for synthesizing benzofuran-indozazaone derivatives as described in claim 1 or 2, characterized in that, The synthesis method includes: Under an inert atmosphere and in the presence of a base and an oxidizing agent [O], compounds 3 and 2 undergo a [4+3] cycloaddition reaction catalyzed by an NHC catalyst to generate benzofuranoindazone derivatives with the molecular structure shown in Formula 1; or, Under an inert atmosphere and in the presence of a base, compounds 3 and 2 undergo a [4+3] cycloaddition reaction catalyzed by an NHC catalyst to generate benzofuran-indozazaone derivatives with the molecular structure shown in Formula 4.

4. The synthesis method according to claim 3, characterized in that, The molar ratio of compound 3 to compound 2 is not less than 1.2:

1.

5. The synthesis method according to claim 3, characterized in that, The reaction is carried out in the presence of a solvent; the solvent includes one or more of toluene, dichloromethane, n-hexane, tetrahydrofuran, and trifluorotoluene. The reaction was carried out in the presence of a 4 Å molecular sieve.

6. The synthesis method according to claim 3, characterized in that, The reaction temperature is 0-35℃; The reaction time is 3-48 hours; The inert atmosphere is a nitrogen atmosphere and / or an argon atmosphere.

7. The synthesis method according to claim 3, characterized in that, The NHC catalyst includes catalyst C: ; Wherein, -C6F5 represents pentafluorophenyl; The molar ratio of the NHC catalyst to compound 2 is not less than 0.2:

1.

8. The synthesis method according to claim 3, characterized in that, The alkali includes one or more of potassium acetate, sodium acetate, sodium benzoate, and potassium benzoate; The molar ratio of the base to compound 2 is not less than 1:

1.

9. The synthesis method according to claim 3, characterized in that, The oxidant [O] includes 3,3',5,5'-tetratert-butyl-4,4'-biphenylquinone; The molar ratio of the oxidant [O] to compound 2 is not less than 1.2:

1.

10. The use of the synthesis method according to any one of claims 3 to 9 in the preparation of a medicament for treating and / or preventing diseases related to abnormal protease activity.